The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical Trial
| Author | Kamal Fani | en |
| Author | Mehdi Ghahremani | en |
| Author | Mohammad Fathi | en |
| Author | Nilofar Massoudi | en |
| Author | Sasan Tavana | en |
| Author | Navid Nooraee | en |
| Author | Nasser Malekpour Alamdari | en |
| Author | Sara Besharat | en |
| Author | Arash Najafi Abrandabadi | en |
| Author | Ali Pirsalehi | en |
| Author | Mohammad Ali Khabiri Khatiri | en |
| Author | Maryam Amini Pouya | en |
| Author | Samira Rajaei | en |
| Author | Ali Dabbagh | en |
| Issued Date | 2021-07-31 | en |
| Abstract | COVID-19 pandemic has created a global health challenge. Many pharmaceuticals have been repurposed as potential treatments, though many have not been promising. Due to the inflammatory and destructive effects of the virus on alveolar cells, the effect of exogenous surfactant was assessed as a potential treatment of lung dysfunction in COVID-19 patients. In this pilot study of the clinical trial, 49 patients aged 35-80 years with COVID-19 admitted in ICU entered the study (22 patients intubated and 23 had face masks; 4 patients in the control arm). The treatment arm patients received two consecutive doses of surfactant. P/F ratio (based on serial blood gas analyses before and 12 hours after 2 doses of surfactant) and also, clinical outcomes were assessed.in COVID-19 adult patients, surfactant significantly improved pulmonary P/F ratio both in intubated and face mask COVID-19 patients (increasing from 119.2 ± 51.7 to 179.4 ± 115.5). The rate of extubation was much better than similar country-wide studies. Surfactant significantly alleviates the respiratory status in moderate to severe COVID-19 ARDS with two consecutive 100 mg doses of surfactant (with 6 hours’ interval) though previous studies have been controversial, regarding the effect of surfactant in general forms of ARDS. Higher doses might have better effects, mandating more trials. | en |
| DOI | https://doi.org/10.22037/ijpr.2021.115390.15347 | en |
| Keyword | COVID-19 | en |
| Keyword | Surfactant | en |
| Keyword | Pulmonary involvement | en |
| Keyword | ARDS | en |
| Publisher | Brieflands | en |
| Title | The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical Trial | en |
| Type | Original Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-20-553.pdf
- Size:
- 311.01 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF